期刊文献+

间歇小剂量环磷酰胺治疗12例狼疮肾炎慢性肾功能不全的临床分析 被引量:1

Clinical evaluation of intermittent low-dosage cyclophosphamide in the treatment of 12 cases with lupus nephritis related chronic renal insufficiency
原文传递
导出
摘要 目的探讨间歇小剂量环磷酰胺(CTX)治疗狼疮肾炎(LN)慢性肾功能不全的有效性及安全性。方法给予12例LN慢性肾功能不全氮质血症期患者间歇小剂量CTX治疗,用量为200~400mg每2~4周,随访2个月~5年,观察12例患者治疗前后的临床转归及实验室改变。结果12例患者疾病活动度(SLEDAI)明显下降。肾功能得到不同程度的改善,9例患者肾功能不全逆转,肌酐降至正常水平,3例仍处于氮质血症期,但较治疗前有所改善。无明显不良反应发生。结论间歇小剂量CTX治疗LN是有效、安全、可行的。但肾功能能否长期改善尚有待大样本的临床观察及长期随访。 Objective To explore the efficacy and safety of intermittent low-dosage intravenous ( Ⅳ ) cyclophosphamide (CTX) in treating lupus nephritis (LN) related chronic renal insufficiency. Methods Twelve patients with chronic renal insufficiency with azotemia caused by lupus nephritis received intermittent low-dosage cyclophosphamide therapy (200+400 mg/2+4 weeks) for 2 month to 5 years. We monitored their clinical outcomes and laboratory parameters changes. Results SLEDAI significantly decreased in all cases. Renal function was improved in varying grees. Nine cases had their renal function tests returned to normal range and another 3 cases were still in azotemia. No severe adverse effects occurred. Conclusion The treatment is effective and safe. But it is necessary to carry out large samples and long-term follow-up clinical studies to evaluate its effects on renal function changes.
出处 《中华风湿病学杂志》 CAS CSCD 2008年第7期484-486,共3页 Chinese Journal of Rheumatology
关键词 环磷酰胺 狼疮肾炎 肾功能衰竭 慢性 治疗 临床研究性 Cyclophosphamide Lupus nephritis Kidney failure, chronic Therapies, investigational
  • 相关文献

参考文献8

  • 1Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med, 2001, 135: 248- 257.
  • 2Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: Controlled trial of prednisolone and cytotoxic drugs. N Engl J Med, 1986, 314: 614- 619.
  • 3Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophos2 phamide. Am J Med, 2006, 119: 26-33.
  • 4Watanabe KN, Duffy CM, Glalman DD. Infection and disease activity in systemic lupus erythematosus: A review of hospitalized patients. J Rheumatol, 1991, 15:1150-1154.
  • 5Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum, 2007, 56: 924-937.
  • 6Contreras G, Pardo V, Leclereq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med, 2004, 350: 971-980.
  • 7Houssiau FA, Vaseoncelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis. Arthritis Rheum, 2002, 46: 2121- 2131.
  • 8Gorman C, Bhatia A, Rahman A. This house believes that low dose intravenous cyclophosphamide is superior to standard highdose regimens for treatment of lupus nephritis. Rheumatology, 2005. 44: 398- 401.

同被引文献10

  • 1Jaekell H P, Trabandt A, Grobe N, et al. Anti-dsDNA antibody subtypes and anti-C1q antibodies:toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis[J]. Lupus, 2006, 15:335 - 345.
  • 2Sinico R A, Radice A, Ikehata M, et al. Anti-Clq autoantibodies in lupus nephritis:prevalence and clinical significance[J]. Ann N Y Acad Sci, 2005, 1050:193-200.
  • 3Houssiau F A, Vasconcelos C, D Cruz D, et al. Immunosuppressive therapy in lupus nephritis : the Euro-Lupus Nephritis Trial, a randomized trial of Iou-dose versus high-dose intravenous Cyclophosphamide[J]. Arthritis Rheum, 2002, 46:2121- 2131.
  • 4Chan T M, Li F K, Tang C S, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis[J]. N Engi J Med, 2000, 343:1156-1162.
  • 5Ginzler E M, Dooley M A, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J]. N Engi J Med, 2005, 353:2219-2228.
  • 6Sinclair A, Appel G, Dooley M A, et al. Mycophenolate mofetilai induction and maintenance therapy fou lupus nephritis:rationale and protocol for the randomized controlled aspreva lupus management suudy[J]. Lupus, 2007, 16:972-980.
  • 7Wang H Y, Gui T G, Hou F F, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multicentre observational study[J]. Lupus, 2008, 17:638-644.
  • 8Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis[J]. N Engi J Med, 2004, 350:971- 980.
  • 9Sfikakis P P, Bolitis J N, Lionaki S, et al. Remission of proliferative lupus nephritis following B ceil depletion therapy is preceded by down-regulation of the T cell costimulatory molecute CD40 ligand:an openlabel trial[J]. Arthritis Rheum, 2005, 52:501-513.
  • 10Schiffer L, Sinha J, Wang X, et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream ou renal immune complex deposition[J].J Immunol, 2003, 17:489-797.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部